🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 124 of 857 · Phase 3 first, then by program name

  1. Oral Treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    2 trials

  2. Oral Treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension Associated With Sickle Cell Disease

    phase 3 small molecule terminated

    1 trial

  3. Oral dexamethasone

    Hospital Authority, Hong Kong

    Bronchiolitis

    phase 3 small molecule completed

    1 trial

  4. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  5. Oral micronized progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  6. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  7. Oral sulfate solution (OSS)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bowel Preparation for Colonoscopy

    phase 3 small molecule completed

    1 trial

  8. Oral treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule terminated

    2 trials

  9. Oral treprostinil (UT-15C) sustained release tablets

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    2 trials

  10. Oral triiodothyronine

    Cardiff Oncology

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  11. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  12. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  13. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  14. Orforglipron

    Eli Lilly and Company

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  15. Orforglipron

    Eli Lilly and Company

    OSA

    phase 3 small molecule active

    1 trial

  16. Orforglipron

    Eli Lilly and Company

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  17. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match LY

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  18. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match, Orforglipron, Orforglipron

    Eli Lilly Co.

    Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  19. Orforglipron, Orforglipron, Orforglipron, Placebo to match ly, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  20. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  21. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  22. Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  23. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  24. Osimertinib

    The First People's Hospital of Lianyungang

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources